Shanghai HeartCare Medical Technology Corporation Limited

SEHK:6609 Stock Report

Market Cap: HK$860.1m

Shanghai HeartCare Medical Technology Management

Management criteria checks 4/4

Shanghai HeartCare Medical Technology's CEO is Guohui Wang, appointed in Jun 2016, has a tenure of 8.5 years. total yearly compensation is CN¥1.17M, comprised of 68.3% salary and 31.7% bonuses, including company stock and options. directly owns 10.05% of the company’s shares, worth HK$86.40M. The average tenure of the management team and the board of directors is 4.1 years and 3.2 years respectively.

Key information

Guohui Wang

Chief executive officer

CN¥1.2m

Total compensation

CEO salary percentage68.3%
CEO tenure8.5yrs
CEO ownership10.0%
Management average tenure4.1yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Even With A 42% Surge, Cautious Investors Are Not Rewarding Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Performance Completely

Sep 27
Even With A 42% Surge, Cautious Investors Are Not Rewarding Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Performance Completely

Some Shareholders Feeling Restless Over Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) P/S Ratio

Aug 01
Some Shareholders Feeling Restless Over Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) P/S Ratio

We're Not Very Worried About Shanghai HeartCare Medical Technology's (HKG:6609) Cash Burn Rate

Jan 23
We're Not Very Worried About Shanghai HeartCare Medical Technology's (HKG:6609) Cash Burn Rate

Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Aug 30
Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth

Aug 09
Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth

Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth

May 07
Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth

We're Hopeful That Shanghai HeartCare Medical Technology (HKG:6609) Will Use Its Cash Wisely

Nov 29
We're Hopeful That Shanghai HeartCare Medical Technology (HKG:6609) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Guohui Wang's remuneration changed compared to Shanghai HeartCare Medical Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥45m

Mar 31 2024n/an/a

-CN¥69m

Dec 31 2023CN¥1mCN¥799k

-CN¥94m

Sep 30 2023n/an/a

-CN¥141m

Jun 30 2023n/an/a

-CN¥188m

Mar 31 2023n/an/a

-CN¥194m

Dec 31 2022CN¥1mCN¥1m

-CN¥200m

Sep 30 2022n/an/a

-CN¥185m

Jun 30 2022n/an/a

-CN¥169m

Mar 31 2022n/an/a

-CN¥188m

Dec 31 2021CN¥21mCN¥1m

-CN¥194m

Sep 30 2021n/an/a

-CN¥242m

Jun 30 2021n/an/a

-CN¥290m

Mar 31 2021n/an/a

-CN¥244m

Dec 31 2020CN¥82mCN¥771k

-CN¥214m

Compensation vs Market: Guohui's total compensation ($USD160.17K) is below average for companies of similar size in the Hong Kong market ($USD231.18K).

Compensation vs Earnings: Guohui's compensation has been consistent with company performance over the past year.

CEO

Guohui Wang (46 yo)

8.5yrs

Tenure

CN¥1,169,000

Compensation

Mr. Guohui Wang is the Chief Executive Officer and Director of Shanghai HeartCare Medical Technology Corporation Limited since June 2016 and serves as its Chairman since November 23, 2020. He served as the...

Leadership Team

NamePositionTenureCompensationOwnership
Guohui Wang
Chairman & CEO8.5yrsCN¥1.17m10.05%
HK$ 86.4m
Kun Zhang
Deputy GM & Executive Director4.1yrsCN¥1.07m3.66%
HK$ 31.4m
Jiawei Wei
Deputy GM & Executive Director4.1yrsCN¥3.47mno data
Han Zhang
CFO & Joint Company Secretary4.1yrsno datano data
Zongyu Xue
VP of Quality Regulation & Employee Representative Supervisorno datano datano data
Siu Ying Kwok
Joint Company Secretary2.8yrsno datano data

4.1yrs

Average Tenure

43yo

Average Age

Experienced Management: 6609's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Guohui Wang
Chairman & CEO8.5yrsCN¥1.17m10.05%
HK$ 86.4m
Kun Zhang
Deputy GM & Executive Director4.1yrsCN¥1.07m3.66%
HK$ 31.4m
Jiawei Wei
Deputy GM & Executive Director2.5yrsCN¥3.47mno data
Zongyu Xue
VP of Quality Regulation & Employee Representative Supervisor1.1yrsno datano data
Shaomu Guo
Independent Non-Executive Director4.1yrsCN¥235.00kno data
Gang Chen
Non-Executive Director1.1yrsno datano data
Kui Ding
Non-Executive Director4.1yrsno data4.11%
HK$ 35.3m
Xiangqian Feng
Independent Non-Executive Director4.1yrsCN¥30.00kno data
Ping Gong
Independent Non-Executive Director3.9yrsCN¥200.00kno data
Shaoxiong Chen
Non-Executive Director2.1yrsCN¥120.00kno data
Xinbei Jiang
Supervisor2.1yrsno datano data
Xue Jiang
Supervisor2.1yrsno datano data

3.2yrs

Average Tenure

41yo

Average Age

Experienced Board: 6609's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:17
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai HeartCare Medical Technology Corporation Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Yuan GaoChina International Capital Corporation Limited
Chris PanGoldman Sachs